Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 12/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679129 | 0.89 | PTPRB (0.49) | PTPRBMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL3606140 | 0.83 | PTPRB (0.58) | PTPRBMEN1KMT2ACCR3 | |
| SCHEMBL3606138 | 0.83 | PTPRB (0.58) | PTPRBMEN1KMT2ACCR3 | |
| SCHEMBL684486 | 0.82 | PTPRB (0.73) | PTPRB | |
| SCHEMBL679208 | 0.81 | PTPRB (0.48) | PTPRBMEN1KMT2ARAB9ACCR3 | |
| SCHEMBL8522780 | 0.79 | PTPRB (0.46) | PTPRBMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL23304105 | 0.78 | PTPRB (0.55) | PTPRBMEN1KMT2ACCR3 | |
| SCHEMBL23304107 | 0.78 | PTPRB (0.55) | PTPRBMEN1KMT2ACCR3 | |
| SCHEMBL23304106 | 0.78 | PTPRB (0.55) | PTPRBMEN1KMT2ACCR3 | |
| SCHEMBL679776 | 0.78 | PTPRB (0.51) | PTPRBMEN1KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150050277-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885MEN1 999/4885KMT2A 3236/4885 |
| US-20150050277-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | PTPRB 2215/4885MEN1 4668/4885KMT2A 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.